New Clinical Data: Effective IOP Reduction in Hispanic Patients with the OMNI® Surgical System

Show Description +

Mark Gallardo, MD, comments on challenges and considerations when managing glaucoma patients from specific populations. Dr. Gallardo is a glaucoma specialist in El Paso, Texas, where 80% of the population is Hispanic, and he stresses the importance of reviewing unique characteristics of specific populations when analyzing study data.

Posted: 8/23/2022

Up Next


OMNI® Surgical System

Real Talk on Interventional Glaucoma – Featuring OMNI Edge

Deborah Ristvedt, DO; Douglas McGraw, DO; and Arkadiy Yadgarov, MD

The Crucial Choice in Combating Glaucoma With Interventional Treatment

Iqbal Ike K. Ahmed, MD, FRCSC; Christine Funke, MD; Zarmeena Vendal, MD; and Reay H. Brown, MD

OMNI® Surgical System in Standalone Cases

Deborah Ristvedt, DO, Neil Patel, MD

Implementing OMNI in Your Practice

Intro to OMNI

Deborah Ristvedt, DO; and Mathew Walker, OD

Patient Selection

Mathew Walker, OD; and Deborah Ristvedt, DO

Patient Education

Deborah Ristvedt, DO; and Mathew Walker, OD

Surgical Consult & Planning

Deborah Ristvedt, DO; and Mathew Walker, OD

Day of Surgery

Deborah Ristvedt, DO

Post-op and Follow up

Deborah Ristvedt, DO; and Mathew Walker, OD

Outcomes and Goals

Deborah Ristvedt, DO; and Mathew Walker, OD

Referral Network

Deborah Ristvedt, DO; and Mathew Walker, OD

Pseudophakic MIGS

About Sight Sciences

New Clinical Data: Effective IOP Reduction in Hispanic Patients with the OMNI® Surgical System

Mark Gallardo, MD, comments on challenges and considerations when managing glaucoma patients from specific populations. Dr. Gallardo is a glaucoma specialist in El Paso, Texas, where 80% of the population is Hispanic, and he stresses the importance of reviewing unique characteristics of specific populations when analyzing study data.

Posted: 8/23/2022

Resources

The Crucial Choice in Combating Glaucoma With Interventional Treatment

View Resource

MIGS Beyond Cataract Surgery: An Interventional Mindset

View Resource

Nine Reasons Why We Perform MIGS with OMNI

View Resource

MIGS Beyond Cataract Surgery

View Resource

Spotlight on OMNI in Standalone Procedures

View Resource

The Benefits of OMNI in Pseudophakic Patients

View Resource

MIGS Algorithm: Navigating A Myriad of Decisions

View Resource

The Changing MIGS Landscape

View Resource

OMNI Surgical System: My First 10 Patients

View Resource

About Sight Sciences

At Sight Sciences, we are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent. Our mission is clear: to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing

Explore more at sightsciences.com

IMPORTANT PRODUCT INFORMATION:

The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Do not use the OMNI® in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI® in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris. Do not use the OMNI® Surgical System in quadrants with previous MIGS implants. Visit omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events.

Doctors are paid consultants of Sight Sciences, Inc.

© 2025 Sight Sciences. Sight Sciences, the Sight Sciences logo, and OMNI are registered trademarks of Sight Sciences. 04/2025 OM-1129-US.v4